(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday - 2Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- 3German finance minister sees advantages of smartphones in schools
- 4From Dread to Certainty: Individual Accounts of Strengthening
- 5Bonk.fun’s April Fools Joke Targets Israel, Sparks Debate
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- Historic underwater structure discovered by divers off French coast
- I visited every country by 25. Antarctica showed me how much I still hadn't seen.
- Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- The Delight of Perusing: Book Proposals for Each Class
- Vote In favor of Your Favored Shades
